# Hercules Bioventure Partners

> Hercules Bioventure Partners is a VC fund in Saratoga backing Biotechnology and Pharmaceutical. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Saratoga, United States
- Total investments: 5
- Last investment: Mar 2025
- Lead investor: 20%
- Last updated: Aug 2026

Hercules Bioventure Partners is a VC fund in Saratoga focused on Biotechnology and Pharmaceutical. Hercules Bioventure Partners, a California-based venture capital firm, serves customers across the United States.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 80% |
| Pharmaceutical | 3 | 60% |
| Biopharma | 2 | 40% |
| Health Care | 2 | 40% |
| Medical | 1 | 20% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 40% |
| Series A | 1 | 20% |
| Post-IPO Equity | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 60% |
| Switzerland | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Apeximmune Therapeutics | Apeximmune Therapeutics is pioneering a new generation of therapeutic antibodies and biologics that harness the power of the immune system to deliver curative treatments for cancer and autoimmune disease. | $21.3M | Series A | Mar 31, 2025 |  |
| BlossomHill Therapeutics | BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. | $100M | Series B | Jan 02, 2024 |  |
| BlossomHill Therapeutics | BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. | $71M | Series A | Mar 03, 2021 |  |
| Addex Therapeutics | Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and mayoffer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID). Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates with a focus in addiction. Preclinical programs ongoing with Addex include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. | $3.5M | Post-IPO Equity | Feb 28, 2017 |  |
| Armetheon | Armetheon, Inc., is a privately held San Francisco Bay area based clinical stage biopharmaceutical company focused on the development of novel drugs for highly unmet need. The company has several programs in clinical stage of development. These include: | $24.3M | Series B | Feb 05, 2015 |  |

5 of 5 investments shown.

## Co-investors
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 2 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 2 deals together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 2 deals together
- Atheneos Ventures — VC Fund, 1 deal together
- [Capital TEN](https://shizune.co/investors/profile/capital-ten-ii) — VC Fund, 1 deal together
- [CDIB Capital](https://shizune.co/investors/profile/cdib-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Hercules Bioventure Partners invest in?

Hercules Bioventure Partners invests primarily in Biotechnology, Pharmaceutical and Biopharma startups, most often at Series B and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Hercules Bioventure Partners last invest?

The most recent investment recorded for Hercules Bioventure Partners closed in Mar 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co